Figure 1. T-MPs function as novel cell-free cancer vaccines. Upon UV irradiation, tumor cells release MPs that contain tumor antigens and DNA fragments. After being taken up by DCs, DNAs of T-MPs induce the expression of type I IFN by activating the cGAS/STING pathway. Type I IFN, in turn, enhances DC maturation by upregulating CD80, CD86, and MHCII. Armed DCs then activate tumor-specific T cells, leading to cytolysis of tumor cells.
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
